Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-07-26
2005-07-26
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387100, C530S387900, C530S387300, C530S388100, C530S388230, C530S389200, C435S325000, C435S326000, C435S007200
Reexamination Certificate
active
06921645
ABSTRACT:
Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
REFERENCES:
patent: 4897348 (1990-01-01), Johnson et al.
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5278287 (1994-01-01), Rollins et al.
patent: 5306709 (1994-04-01), Gewirtz
patent: 5346686 (1994-09-01), Lyle et al.
patent: 5413778 (1995-05-01), Kunkel et al.
patent: 5474983 (1995-12-01), Kuna et al.
patent: 5602008 (1997-02-01), Wilde et al.
patent: 5936068 (1999-08-01), Wilde et al.
patent: 6096300 (2000-08-01), Hromas
patent: 6174995 (2001-01-01), Li et al.
patent: 0538 030 2 (1993-04-01), None
patent: 07-089866 (1995-04-01), None
patent: WO-90/06321 (1990-06-01), None
patent: WO-91/04274 (1991-04-01), None
patent: WO-91/12815 (1991-09-01), None
patent: WO-92/05198 (1992-04-01), None
patent: WO-92/20372 (1992-11-01), None
patent: WO-95/17092 (1995-06-01), None
patent: WO-95/31467 (1995-11-01), None
patent: WO-95/31468 (1995-11-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/06169 (1996-02-01), None
patent: WO-96-09062 (1996-03-01), None
patent: WO-96/16979 (1996-06-01), None
patent: WO-96/39520 (1996-12-01), None
patent: WO-96/39521 (1996-12-01), None
patent: WO-96/39522 (1996-12-01), None
patent: WO-97/31098 (1997-03-01), None
patent: WO-97/15594 (1997-05-01), None
patent: WO-97-15595 (1997-05-01), None
patent: WO-97/35982 (1997-10-01), None
patent: WO-98/01557 (1998-01-01), None
patent: WO-98/09171 (1998-03-01), None
patent: WO-98/11226 (1998-03-01), None
patent: WO-98/14573 (1998-04-01), None
patent: WO-98/17800 (1998-04-01), None
patent: WO-98/21330 (1998-05-01), None
patent: WO-99/47674 (1999-09-01), None
Skolnick et al. Nature Biotechnology. Mar. 2000, vol. 18, pp. 283-287.
Lin et al., “Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response toPseudomonas aeruginosa,”Infect. Immun., 71(1):365-373 (Jan. 2003).
Nishi et al., “Involvement of Myeloid Dendritic Cells in the Development of Gastric Secondary Lymphoid Follicles in Helicobacter pylori-Infected Neonatally Thymectomized BALB/c Mice,”Infect. Immun., 71(4):2153-2162 (Apr. 2003).
Sierro et al., “Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells,”PNAS, 98(24):13722-13727 (Nov. 20, 2001).
Bennouna et al., “Cross-Talk in the Innate Immune System: Neutrophils Instruct Recruitment and Activation of Dendritic Cells during Microbial Infection,”J. Immunol., 171:6052-6058 (2003).
Hoover et al., “The Structure of Human Macrophage Inflammatory Protein-3alpha/CCL20—Linking Antimicrobial and CC Chemokine Receptor-6-Binding Activities With Human Beta-Defensins,”J. Biol. Chem., 277(40):37647-37654 (Oct. 4, 2002).
Yang et al., “Many chemokines including CCL20/MIP-3alpha display antimicrobial activity,”J. Leukoc. Biol., 74(3):448-455 (Sep. 2003).
Matsui et al., “Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis,”Clin. Exp. Immunol., 125(1):155-161 (Jul. 2001).
Ruth et al., “Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis,”Lab. Invest., 83(4):579-588 (Apr. 2003).
Kwon et al., “Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease,”Gut, 51(6):818-826 (Dec. 2002).
Ambrosini et al., “Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro,”Glia, 41(3):290-300 (Feb. 2003).
Kohler et al., “A Role for Macrophage Inflammatory Protein-3alpha/CC Chemokine Ligand 20 in Immune Priming During T Cell-Mediated Inflammation of the Central Nervous System,”J. Immunol., 170:6298-6306 (2003).
Fushimi et al., “Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth,”J. Clin. Invest., 105(10):1383-1393 (May 2000).
Crittenden et al., “Expression of Inflammatory Chemokines Combined with Local Tumor Destruction Enhances Tumor Regression and Long-term Immunity,”Cancer Res., 63:5505-5512 (Sep. 1, 2003).
Abiko et al., “Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma,”Arch. Oral Biol., 48(2):171-175 (Feb. 2003).
Akahoshi et al., “Production of Macrophage Inflammatory Protein 3 (MIP-3) (CCL20) and MIP-3 (CCL19) by Human Peripheral Blood Neutrophils in Response to Microbial Pathogens,”Infect. Immun., 71(1):524-526 (Jan. 2003).
Dieu-Nosjean et al., “Macrophage Inflammatory Protein 3 Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors,”J. Exp. Med., 192(5):705-717 (Sep. 2002).
Homey et al., “Up-Regulation of Macrophage Inflammatory Protein-3/CCL20 and CC Chemokine Receptor 6 in Psoriasis,”J. Immunol., 164:6621-6632 (2000).
Hosokawa et al., “Macrophage inflammatory protein 3alpha-CC chemokine receptor 6 interactions play an important role in CD4+ T-cell accumulation in periodontal diseased tissue,”Clin. Exp. Immunol., 128(3):548-554 (Jun. 2002).
Kleeff et al., “Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer,”Int. J. Cancer, 81(4):650-657 (May 17, 1999).
Genbank Accession No. I35613 (1997).
Genbank Accession No. AAB38703 (1996).
Genbank Accession No. U77035 (1997).
Genbank Accession No. CAA66950 (1998).
Genbank Accession No. U46767 (1997).
Genbank Accession No. D86955 (1997).
Genbank Accession No. X98306 (1998).
GeneSeq Accession No. W17660 (1997).
GeneSeq Accession No. R95690 (1996).
GeneBank Accession No. U64197 (1997).
GeneSeq Accession No. W44398 (1998).
GeneSeq Accession No. W61279 (1998).
GeneSeq Accession No. W57475 (1998).
GeneSeq Accession No. T90880 (1998).
GeneSeq Accession No. V28591 (1998).
GeneSeq Accession No. T90883 (1998).
GeneBank Accession No. W30191 (1998).
GenBank Accession No: AAC50943.1 (Aug. 06, 1996).
GenBank Accession No: AAB61534.1 (Aug. 06, 1996).
GenBank Accession No: AA739063 (Jan. 14, 1998).
GenBank Accession No: T27336 (Dec. 06, 1994).
GenBank Accession No: AI735669 (Jun. 14, 1999).
GenBank Accession No: T27433 (Dec. 06, 1994).
GenBank Accession No: D31065 (Feb. 08, 1995).
GenBank Accession No: AA297433 (Apr. 18, 1997).
GenBank Accession No: AJ001634 (Sep. 10, 1997).
GenBank Accession No: AJ000979 (Jun. 30, 1997).
GenBank Accession No: AC002482 (Aug. 21, 1997).
GenBank Accession No: Z77650 (Jul. 30, 1996).
GenBank Accession No: Z77651 (Jul. 30, 1996).
GenBank Accession No:CAA04888 (Sep. 10, 1997).
GenBank Accession No: CAB01111 (Jul. 30, 1996).
GenBank Accession No: CAB01112 (Jul. 30, 1996).
GenBank Accession No: AI925360 (Jul. 30, 1999).
GenBank Accession No: AA403048 (Apr. 29, 1997).
GenBank Accession No: AA404346 (Apr. 30, 1997).
GenBank Accession No: AA426245 (May 19, 1997).
GenBank Accession No: T64134 (Feb, 17, 1995).
GenBank Accession No: T64262 (Feb. 17, 1995).
GenBank Accession No: D17181 (Jul. 21, 1993)
Adams Mark D.
Li Haodong
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Mertz Prema
LandOfFree
Antibodies to chemokine β-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to chemokine β-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to chemokine β-4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395461